Trial results reinforce dabigatran safety in AF

The US regulator’s investigation of post-marketing reports of gastrointestinal and intracranial bleeding among new users found the risk was no greater than with warfarin and was consistent with the results of the RELY clinical trial used for approval.

Manufacturer Boehringer Ingelheim also announced results of the RELY-ABLE extension trial at the American Heart Association Scientific Sessions last week. It followed 5851 patients for over two years, including about 100 Australian